Parkinson's Disease is a chronic and progressive degenerative
disease caused by the gradual degeneration of dopamine producing neuron cells,
which are distributed over the substantia nigra, that bring forth characteristic
symptoms such as rigidity, slowed movement, tremor, and unstable posture and balance.
It is estimated that approximately 2~3% of those over 65 are diagnosed with this disease.

Clinician still don’t know exactly what causes Parkinson's disease, they think it’s probably due to a combination of genetic and environmental factors. People with parents who developed Parkinson’s at a younger age face an increased risk up to 15 %.

Specific genetic factors appear to play a strong role in early-onset Parkinson's disease, an uncommon form of the disease. Multiple genetic factors including mutation may also be involved in some cases of late-onset of Parkinson's disease.

Parkinson’s disease is a neurological disorder that affects movement, muscle control, and balance. Parkinson’s disease most commonly affects people 55 - 75 years old, but it can also develop in 10-15 % of younger people under 50 years old. The disease is usually progressive, with symptoms becoming more severe over time.

Other than typical motion related symptoms, Parkinson’s disease also causes non-motor symptoms, including sleep problems, gastrointestinal, urinary disorders, sexual dysfunction, decrease sense of smell, depression and anxiety.

According to Global Data report, the Parkinson's disease market in seven major countries (the United States, Japan, France, Germany, Italy, Spain and the United Kingdom) was 3.1 billion dollars in 2016 and the U.S. market accounted for 50.2 percent of the total market. The parkinson's disease market is expected to grow at an annual rate of 11.1% to $8.8 billion in 2026 (GlobalData, 2018). A major driving force behind this is the increase in the global population and advancements in healthcare that contribute to an aging population at increased risk for Parkinson’s disease.

The population of Parkinson’s disease patients is expected to increase from 3.2 million people in 2012 to 4.3 million in 2022 in the seven major markets (Global Data, March 2014). The market for Parkinson’s disease is the second most common neurological disorder, with an increased prevalence in the elderly.